Literature DB >> 20668910

RhoA/Rho-kinase and vascular diseases: what is the link?

Kenia Pedrosa Nunes1, Christine S Rigsby, R Clinton Webb.   

Abstract

RhoA/Rho-kinase pathway plays an important role in many pathological conditions. RhoA participates in the regulation of smooth muscle tone and activates many downstream kinases. The best characterized are the serine/threonine kinase isoforms (Rho-kinase or ROCK), ROCKα/ROCK2 and ROCKβ/ROCK1. ROCK is necessary for diverse functions such as local blood flow, arterial/pulmonary blood pressure, airway resistance and intestinal peristalsis. ROCK activation permits actin/myosin interactions and smooth muscle cells contraction by maintaining the activity of myosin light-chain kinase, independently of the free cytosolic calcium level. The sensitization of smooth muscle myofilaments to calcium has been implicated in many pathological states, such as hypertension, diabetes, heart attack, stroke, pulmonary hypertension, erectile dysfunction, and cancer. The focus of this review is on the involvement of RhoA/Rho-kinase in diseases. We will briefly describe the ROCK isoforms and the role of RhoA/Rho-kinase in the vasculature, before exploring the most recent findings regarding this pathway and various diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668910      PMCID: PMC2996825          DOI: 10.1007/s00018-010-0460-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  168 in total

Review 1.  Diabetes and cardiovascular disease.

Authors:  J R Sowers; M A Lester
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

2.  p116Rip decreases myosin II phosphorylation by activating myosin light chain phosphatase and by inactivating RhoA.

Authors:  Yasuhiko Koga; Mitsuo Ikebe
Journal:  J Biol Chem       Date:  2004-11-14       Impact factor: 5.157

3.  Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.

Authors:  Hwa Kyoung Shin; Salvatore Salomone; E Michelle Potts; Sae-Won Lee; Eric Millican; Kensuke Noma; Paul L Huang; David A Boas; James K Liao; Michael A Moskowitz; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-11       Impact factor: 6.200

4.  Rho proteins induce metastatic properties in vivo.

Authors:  L del Peso; R Hernández-Alcoceba; N Embade; A Carnero; P Esteve; C Paje; J C Lacal
Journal:  Oncogene       Date:  1997-12-18       Impact factor: 9.867

5.  Elevated concentrations of sphingosylphosphorylcholine in cerebrospinal fluid after subarachnoid hemorrhage: a possible role as a spasmogen.

Authors:  Tetsu Kurokawa; Yasunobu Yumiya; Hirosuke Fujisawa; Satoshi Shirao; Shiro Kashiwagi; Masafumi Sato; Hiroko Kishi; Saori Miwa; Kimiko Mogami; Shoichi Kato; Tatsuo Akimura; Masaaki Soma; Kuniaki Ogasawara; Akira Ogawa; Sei Kobayashi; Michiyasu Suzuki
Journal:  J Clin Neurosci       Date:  2009-08       Impact factor: 1.961

Review 6.  High-normal blood pressure and the risk of cardiovascular disease.

Authors:  Yoshihiro Kokubo; Kei Kamide
Journal:  Circ J       Date:  2009-07-14       Impact factor: 2.993

Review 7.  Smooth muscle cell calcium activation mechanisms.

Authors:  Michael J Berridge
Journal:  J Physiol       Date:  2008-09-11       Impact factor: 5.182

8.  Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts.

Authors:  Naohiko Kobayashi; Hiroshi Takeshima; Hiromichi Fukushima; Wataru Koguchi; Yasuko Mamada; Hisato Hirata; Yoshifumi Machida; Motoo Shinoda; Noriko Suzuki; Fumie Yokotsuka; Kyoko Tabei; Hiroaki Matsuoka
Journal:  Am J Hypertens       Date:  2008-11-27       Impact factor: 2.689

9.  Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.

Authors:  Shin-ichi Satoh; Yoshinori Toshima; Asako Hitomi; Ichiro Ikegaki; Minoru Seto; Toshio Asano
Journal:  Brain Res       Date:  2007-12-04       Impact factor: 3.252

10.  Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.

Authors:  Vasantha Kolavennu; Lixia Zeng; Hui Peng; Yin Wang; Farhad R Danesh
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461

View more
  66 in total

1.  Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.

Authors:  Tsung-Jung Ho; Chi-Chang Huang; Chih-Yang Huang; Wan-Teng Lin
Journal:  Eur J Appl Physiol       Date:  2011-12-09       Impact factor: 3.078

Review 2.  Role of rho kinase in the functional and dysfunctional tonic smooth muscles.

Authors:  Márcio A F de Godoy; Satish Rattan
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

Review 3.  Rho-kinase: regulation, (dys)function, and inhibition.

Authors:  Ehsan Amin; Badri Nath Dubey; Si-Cai Zhang; Lothar Gremer; Radovan Dvorsky; Jens M Moll; Mohamed S Taha; Luitgard Nagel-Steger; Roland P Piekorz; Avril V Somlyo; Mohammad R Ahmadian
Journal:  Biol Chem       Date:  2013-11       Impact factor: 3.915

Review 4.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

5.  Regulation of RhoA signaling by the cAMP-dependent phosphorylation of RhoGDIα.

Authors:  Atsuro Oishi; Noriko Makita; Junichiro Sato; Taroh Iiri
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

Review 6.  Protecting against vascular disease in brain.

Authors:  Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

7.  Constriction of retinal arterioles to endothelin-1: requisite role of rho kinase independent of protein kinase C and L-type calcium channels.

Authors:  Luke B Potts; Yi Ren; Guangrong Lu; Enoch Kuo; Ellen Ngo; Lih Kuo; Travis W Hein
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

Review 8.  Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.

Authors:  Takayuki Matsumoto; Styliani Goulopoulou; Kumiko Taguchi; Rita C Tostes; Tsuneo Kobayashi
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

Review 9.  The effect of aging on the cutaneous microvasculature.

Authors:  Itay Bentov; May J Reed
Journal:  Microvasc Res       Date:  2015-04-24       Impact factor: 3.514

10.  Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery.

Authors:  Shun Watanabe; Takayuki Matsumoto; Mirai Oda; Kosuke Yamada; Junya Takagi; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2015-11-17       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.